Diabetic eye disease is the leading cause of blindness worldwide, affecting all eye tissues including the cornea. Over 70% of diabetics suffer from corneal problems that can reduce vision and cause pain, such as neuropathy and various epithelial alterations referred to as diabetic keratopathy. Keratopathy is more pronounced in severe diabetes but is under-diagnosed;its therapy remains symptomatic. Our gene therapy in organ-cultured human corneas using sufficiently safe replication-deficient adenovirus (AV) showed that: (1) Sildenafil enhanced AV epithelial delivery;(2) In diabetic corneas, c-met proto-oncogene upregulation normalized expression of specific proteins and epithelial wound healing via p38 activation;(3) In normal corneas, upregulation of cathepsin F and matrix metalloproteinase (MMP)-10 that are increased in diabetic corneas delayed wound healing and changed marker expression towards diabetic;this occurred via inhibiting Akt activity;(4) When proteinase genes were silenced using AV-shRNA, diabetic corneas healed faster. AV gene therapy was able to correct key epithelial abnormalities associated with diabetic keratopathy. We also show that several presumed stem cell markers had a decreased expression in the diabetic limbal epithelium making it an important target of gene therapy. Our main hypothesis is that deficiencies in the limbal epithelium of diabetic patients ultimately lead to corneal epithelial abnormalities. These defects may be corrected by targeting limbal epithelial cells with gene therapy as a promising approach to the treatment of diabetic keratopathy. Based on this hypothesis, we propose the following Specific Aims:
Specific Aim 1. To examine whether AV-driven gene therapy on limbal epithelial cells reverses the diabetic marker protein expression pattern and facilitates epithelial wound healing of organ-cultured diabetic corneas. We predict that our gene therapy will restore presumed stem cell marker expression and epithelial wound healing in diabetic corneas towards normal.
Specific Aim 2. To determine if overexpression of c-met and downregulation of MMP-10 and cathepsin F normalizes marker expression pattern and wound healing of diabetic limbal epithelial cells cultured on amniotic membrane. We predict that gene therapy will normalize cultured diabetic limbal cells for their use as substitutes for pathologically altered diabetic limbal epithelium in Aim 3.
Specific Aim 3. To achieve transplantation of genetically modified cultured limbal cells to the limbal zone of diabetic corneas in order to restore normal stem cell marker expression and wound healing. We predict that gene therapy will normalize diabetic limbal epithelial cells, so that transplanting them into the limbal region of a diabetic cornea will restore its normal wound healing and marker protein expression. Health relevance: our novel strategy of targeting corneal epithelial progenitor cell niche by gene therapy may lead to a new treatment for diabetic keratopathy, a serious clinical problem affecting the majority of diabetics.

Public Health Relevance

The application addresses PA-10-067 goal as a Research Project Grant on a new mechanism and treatment approach of diabetic corneal disease. We will focus on corneal epithelial progenitor cells, which are the source of corneal surface lining, as a new target of specific gene therapy aiming at normalizing their functions in order to restore normal protein expression and wound healing in diabetic corneas. If successful, the application may have a high impact for future treatment of frequent corneal problems in diabetic patients.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Anterior Eye Disease Study Section (AED)
Program Officer
Mckie, George Ann
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cedars-Sinai Medical Center
Los Angeles
United States
Zip Code
Leszczynska, Aleksandra; Kulkarni, Mangesh; Ljubimov, Alexander V et al. (2018) Exosomes from normal and diabetic human corneolimbal keratocytes differentially regulate migration, proliferation and marker expression of limbal epithelial cells. Sci Rep 8:15173
Ljubimov, Alexander V (2017) Diabetic complications in the cornea. Vision Res 139:138-152
Daliri, Karim; Ljubimov, Alexander V; Hekmatimoghaddam, Seyedhossein (2017) Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now? Int J Stem Cells 10:119-128
Kulkarni, Mangesh; Leszczynska, Aleksandra; Wei, Gabbie et al. (2017) Genome-wide analysis suggests a differential microRNA signature associated with normal and diabetic human corneal limbus. Sci Rep 7:3448
Ljubimova, Julia Y; Sun, Tao; Mashouf, Leila et al. (2017) Covalent nano delivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev 113:177-200
Saghizadeh, Mehrnoosh; Kramerov, Andrei A; Svendsen, Clive N et al. (2017) Concise Review: Stem Cells for Corneal Wound Healing. Stem Cells 35:2105-2114
Ljubimov, Alexander V (2017) Cell Therapy for Age-Related Macular Degeneration: A New Vision for the Bone Marrow? Mol Ther 25:832-833
Kramerov, Andrei A; Saghizadeh, Mehrnoosh; Ljubimov, Alexander V (2016) Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells. J Vis Exp :e54058
Kramerov, Andrei A; Ljubimov, Alexander V (2016) Stem cell therapies in the treatment of diabetic retinopathy and keratopathy. Exp Biol Med (Maywood) 241:559-68
Chou, Szu-Ting; Patil, Rameshwar; Galstyan, Anna et al. (2016) Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release 244:14-23

Showing the most recent 10 out of 41 publications